Weekly Investment Analysts’ Ratings Changes for Beta Bionics (BBNX)

Beta Bionics (NASDAQ: BBNX) recently received a number of ratings updates from brokerages and research firms:

• 10/6/2026 – Beta Bionics is now covered by Barclays PLC. They set an “overweight” rating and a $30.00 price target on the stock.
• 10/6/2026 – Beta Bionics was upgraded by Barclays PLC to “strong-buy”.
• 9/24/2026 – Beta Bionics had its price target raised by Truist Financial Corporation from $23.00 to $28.00. They now have a “buy” rating on the stock.
• 9/23/2026 – Beta Bionics is now covered by Wells Fargo & Company. They set an “overweight” rating and a $28.00 price target on the stock.
• 9/23/2026 – Beta Bionics is now covered by Wells Fargo & Company. They set an “overweight” rating and a $28.00 price target on the stock.
• 9/19/2026 – Beta Bionics was upgraded by Wall Street Zen from “sell” to “hold”.
• 9/15/2026 – Beta Bionics had its “buy” rating reaffirmed by Truist Financial Corporation. They now have a $23.00 price target on the stock, up from $22.00.
• 9/15/2026 – Beta Bionics had its “buy” rating reaffirmed by UBS Group AG. They now have a $25.00 price target on the stock.
• 9/15/2026 – Beta Bionics had its price target raised by Bank of America Corporation from $18.00 to $20.00. They now have a “neutral” rating on the stock.
• 9/15/2026 – Beta Bionics had its price target raised by Robert W. Baird from $14.00 to $16.00. They now have a “neutral” rating on the stock.
• 9/14/2026 – Beta Bionics had its price target raised by Leerink Partners from $24.00 to $27.00. They now have an “outperform” rating on the stock.
• 8/21/2026 – Beta Bionics is now covered by William Blair. They set a “market perform” rating on the stock.
• 8/18/2026 – Beta Bionics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.

Insider Buying and Selling at Beta Bionics

In related news, CFO Stephen Feider sold 6,675 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $19.11, for a total value of $127,559.25. Following the transaction, the chief financial officer owned 159,378 shares in the company, valued at $3,045,713.58. This trade represents a 4.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Mark Hopman sold 36,870 shares of the business’s stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $18.46, for a total value of $680,620.20. Following the sale, the insider directly owned 87,157 shares of the company’s stock, valued at $1,608,918.22. This represents a 29.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 97,697 shares of company stock valued at $1,907,034 over the last ninety days. Company insiders own 5.30% of the company’s stock.

Beta Bionics, Inc is a medical technology company focused on developing and commercializing automated insulin delivery systems for people with insulin-requiring diabetes. Its lead product is the iLet Bionic Pancreas, an insulin pump system designed to automate much of the insulin-dosing process and reduce the daily burden associated with diabetes management.

The iLet Bionic Pancreas uses continuous glucose monitoring data and the company’s dosing algorithms to deliver insulin. Unlike conventional insulin pumps that generally require users to calculate meal doses, the system is designed to simplify mealtime dosing by using a person’s body weight and meal announcements as key inputs.